Janux Therapeutics, Inc.
JANX
$24.31
$1.044.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -82.56% | 741.72% | -38.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -82.56% | 741.72% | -38.87% |
| Cost of Revenue | 78.07% | 69.97% | 56.53% | -0.17% | -11.31% |
| Gross Profit | -95.47% | -112.74% | -93.87% | 56.72% | 7.23% |
| SG&A Expenses | 34.03% | 29.24% | 174.42% | 13.66% | 13.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.97% | 56.05% | 97.93% | 4.19% | -4.10% |
| Operating Income | -73.09% | -79.85% | -126.66% | 33.38% | 0.59% |
| Income Before Tax | -59.27% | -71.93% | -142.56% | 65.96% | 15.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.27% | -71.93% | -142.56% | 65.96% | 15.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.27% | -71.93% | -142.56% | 65.96% | 15.46% |
| EBIT | -73.09% | -79.85% | -126.66% | 33.38% | 0.59% |
| EBITDA | -75.14% | -82.69% | -130.73% | 34.33% | 1.00% |
| EPS Basic | -26.42% | -41.21% | -102.92% | 73.86% | 28.01% |
| Normalized Basic EPS | -26.42% | -41.23% | -102.91% | 73.85% | 28.01% |
| EPS Diluted | -26.42% | -41.21% | -102.92% | 73.86% | 28.01% |
| Normalized Diluted EPS | -26.42% | -41.23% | -102.91% | 73.85% | 28.01% |
| Average Basic Shares Outstanding | 25.98% | 21.74% | 19.52% | 30.15% | 17.44% |
| Average Diluted Shares Outstanding | 25.98% | 21.74% | 19.52% | 30.15% | 17.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |